ASTRI and NAMI Complete Strategic Merger to Propel Hong Kong's Innovation Leadership

ASTRI and NAMI Complete Strategic Merger to Propel Hong Kong's Innovation Leadership

HONG KONG, April 1, 2026 /PRNewswire/ -- The Hong Kong Applied Science and Technology Research Institute (ASTRI) today announced the successful completion of its merger with the Nano and Advanced Materials Institute (NAMI), creating Hong Kong's...

Türk Telekom and ZTE Complete World's First C+L Full-Band Integrated 1.6Tbps Live Network Trial, Ushering in A New Era of 5G All-Optical Network

Türk Telekom and ZTE Complete World's First C+L Full-Band Integrated 1.6Tbps Live Network Trial, Ushering in A New Era of 5G All-Optical Network

BARCELONA, Spain, March 5, 2026 /PRNewswire/ -- ZTE Corporation (0763.HK / 000063.SZ), a global leading provider of integrated information and communication technology solutions, and Türk Telekom have jointly completed the world's first C+L (12 THz)...

CIMB Niaga and Virtusa Complete a First-of-Its-Kind Modernization on Pega Cloud to Enhance Customer Banking Experiences in Indonesia

CIMB Niaga and Virtusa Complete a First-of-Its-Kind Modernization on Pega Cloud to Enhance Customer Banking Experiences in Indonesia

Milestone accelerates cloud adoption and sets a new standard for digital banking modernization across Indonesia SOUTHBOROUGH, Mass., Feb. 26, 2026 /PRNewswire/ -- Virtusa Corporation, a global product and platform engineering services company, today...

TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids

TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids

Primary Endpoint Met: Statistically significant reduction in heavy menstrual bleeding achieved in all dosage of Merigolix groups compared to placebo Broader Therapeutic Potential: Positive Phase 2 results in both uterine fibroids and endometriosis...

menu
menu